Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...

Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion YK-hBCMA BB-002, despite high-risk biology and frailty representation. Depth of ...

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...

The Keystone Central Foundation celebrated the accomplishments of distinguished graduates and community leaders Thursday, March 12, during their fifth annual Keystone Central Alumni Hall of Fame ...

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes ...

Peter Thiel and other tech billionaires are publicly shielding their children from the products that made them rich Former ...

Risankizumab showed high rates of clinical remission and endoscopic response when administered as subcutaneous induction therapy for moderate to severe CD.

While there is no cure for ANCA-associated vasculitis (AAV), treatment is usually very effective at bringing it under control and preventing life-threatening complications. This group of rare ...

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation After 2 weeks of induction ...